Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
ObjectiveTo compare the efficacy and safety of programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) and programmed cell death ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) for the treatment of extensive-stage small-cell lung cancer (ES-SCLC).MethodsWe performed a meta-analysis...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1455306/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583775362482176 |
|---|---|
| author | Ke Wang Ke Wang Chuangjie Zheng Chuangjie Zheng Xinrong Chen Xinrong Chen Penghui Lin Mengge Lin Cuizhen Chen Linzhu Zhai |
| author_facet | Ke Wang Ke Wang Chuangjie Zheng Chuangjie Zheng Xinrong Chen Xinrong Chen Penghui Lin Mengge Lin Cuizhen Chen Linzhu Zhai |
| author_sort | Ke Wang |
| collection | DOAJ |
| description | ObjectiveTo compare the efficacy and safety of programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) and programmed cell death ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) for the treatment of extensive-stage small-cell lung cancer (ES-SCLC).MethodsWe performed a meta-analysis of relevant data using R software, considering overall survival (OS), progression-free survival (PFS), and grade ≥ 3 treatment-related adverse events (TRAES).ResultsPD-1 + Chemo (OS: hazard ratio [HR] 0.71; PFS: HR 0.59) and PD-L1 + Chemo (OS: HR 0.72; PFS: HR 0.73) significantly prolonged survival and did not increase the incidence of grade ≥3 TRAEs compared with chemotherapy. Indirect comparisons showed no significant difference in clinical efficacy (OS: HR 0.99, 95% CI: 0.86–1.1; PFS: HR 0.80, 95% CI: 0.61–1.0) or safety (HR 1.0, 95% CI: 0.93–1.1) between PD-1 + Chemo and PD-L1 + Chemo. Non-cumulative probability ranking plot ranking results showed that PD-1 + Chemo ranked first in OS and PFS. Patients with PD-L1 expression levels < 1%, PD-1 + Chemo showed a trend of disadvantage (OS: HR 1.3; PFS: HR 1.2), whereas for patients with PD-L1 expression levels ≥ 1%, PD-1 + Chemo showed a trend of advantage (OS: HR 0.85; PFS: HR 0.85).ConclusionsPD-1 + Chemo and PD-L1 + Chemo significantly prolonged OS and PFS in patients with ES-SCLC and did not significantly increase the incidence of grade ≥ 3 TRAES. The efficacy and safety profiles of PD-1 + Chemo and PD-L1 + Chemo appear to be similar. |
| format | Article |
| id | doaj-art-4a968a01f31349c39e3c90698afe188e |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-4a968a01f31349c39e3c90698afe188e2025-01-28T05:10:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14553061455306Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancerKe Wang0Ke Wang1Chuangjie Zheng2Chuangjie Zheng3Xinrong Chen4Xinrong Chen5Penghui Lin6Mengge Lin7Cuizhen Chen8Linzhu Zhai9Guangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangzhou University of Chinese Medicine, Guangzhou, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou, ChinaCancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaCancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaCancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaCancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, ChinaObjectiveTo compare the efficacy and safety of programmed cell death 1 inhibitors plus chemotherapy (PD-1 + Chemo) and programmed cell death ligand 1 inhibitors plus chemotherapy (PD-L1 + Chemo) for the treatment of extensive-stage small-cell lung cancer (ES-SCLC).MethodsWe performed a meta-analysis of relevant data using R software, considering overall survival (OS), progression-free survival (PFS), and grade ≥ 3 treatment-related adverse events (TRAES).ResultsPD-1 + Chemo (OS: hazard ratio [HR] 0.71; PFS: HR 0.59) and PD-L1 + Chemo (OS: HR 0.72; PFS: HR 0.73) significantly prolonged survival and did not increase the incidence of grade ≥3 TRAEs compared with chemotherapy. Indirect comparisons showed no significant difference in clinical efficacy (OS: HR 0.99, 95% CI: 0.86–1.1; PFS: HR 0.80, 95% CI: 0.61–1.0) or safety (HR 1.0, 95% CI: 0.93–1.1) between PD-1 + Chemo and PD-L1 + Chemo. Non-cumulative probability ranking plot ranking results showed that PD-1 + Chemo ranked first in OS and PFS. Patients with PD-L1 expression levels < 1%, PD-1 + Chemo showed a trend of disadvantage (OS: HR 1.3; PFS: HR 1.2), whereas for patients with PD-L1 expression levels ≥ 1%, PD-1 + Chemo showed a trend of advantage (OS: HR 0.85; PFS: HR 0.85).ConclusionsPD-1 + Chemo and PD-L1 + Chemo significantly prolonged OS and PFS in patients with ES-SCLC and did not significantly increase the incidence of grade ≥ 3 TRAES. The efficacy and safety profiles of PD-1 + Chemo and PD-L1 + Chemo appear to be similar.https://www.frontiersin.org/articles/10.3389/fonc.2024.1455306/fullextensive-stage small-cell lung cancerefficacy and safetyPD-1 inhibitorsPD-L1 inhibitorsnetwork meta-analysis |
| spellingShingle | Ke Wang Ke Wang Chuangjie Zheng Chuangjie Zheng Xinrong Chen Xinrong Chen Penghui Lin Mengge Lin Cuizhen Chen Linzhu Zhai Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer Frontiers in Oncology extensive-stage small-cell lung cancer efficacy and safety PD-1 inhibitors PD-L1 inhibitors network meta-analysis |
| title | Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer |
| title_full | Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer |
| title_fullStr | Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer |
| title_full_unstemmed | Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer |
| title_short | Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer |
| title_sort | updated bayesian network meta analysis on the efficacy and safety of pd 1 versus pd l1 inhibitors in first line treatment with chemotherapy for extensive stage small cell lung cancer |
| topic | extensive-stage small-cell lung cancer efficacy and safety PD-1 inhibitors PD-L1 inhibitors network meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1455306/full |
| work_keys_str_mv | AT kewang updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT kewang updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT chuangjiezheng updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT chuangjiezheng updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT xinrongchen updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT xinrongchen updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT penghuilin updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT menggelin updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT cuizhenchen updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer AT linzhuzhai updatedbayesiannetworkmetaanalysisontheefficacyandsafetyofpd1versuspdl1inhibitorsinfirstlinetreatmentwithchemotherapyforextensivestagesmallcelllungcancer |